Feature | Cardiovascular Clinical Studies | May 14, 2018

Psoriasis Therapy Can Reduce Coronary Plaque

First-in-human observational study examines short-term relationship between FDA-approved treatment chronic inflammatory skin disease and coronary plaque inflammation

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin disease, can help reduce coronary plaque. The authors found that not only do the treatments reduce the volume of the plaque, but also the plaque becomes less inflammatory over time, harboring fewer characteristics prone to rupture and cause a heart attack. It is the first-in-human observational study demonstrating that treating remote inflammation in the body can modulate coronary disease. It was presented at the 2018 Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Sessions by Research Fellow Youssef Elnabawi from the National Heart, Lung, and Blood Institute in Bethesda, Maryland.[1]

In the United States, there are about 150,000 new cases of PSO every year, and the disease affects more than 7.5 million people.[2] It is associated with an accelerated risk of myocardial infarction,[3] and has increased risk for atherogenesis, which is the development of plaque within the walls of blood vessels.[4] For the first time, recent evidence demonstrated a significant reduction in adverse cardiovascular events targeting interleukin-1 beta (IL1B), a cytokine that is central to the inflammatory response.[5]

The authors worked to identify if treatment of the inflammatory skin disease potentially affected coronary plaque. Anti-tumor necrosis factor (TNF) agents are commonly used, biologic, and FDA-approved immunomodulatory treatment options for PSO. More than 80 consecutive patients were stratified by biologic treatment (predominantly anti-TNF; n=57) and non-biologic treatment (n= 27). Non-calcified burden (NCB), plaque volume (PV), and maximal artery stenosis in the proximal vessels (diameter more than 2mm) were blindly assessed based on coronary CT angiography using dedicated software.

The patients were middle-aged and at low cardiovascular risk by traditional risk scores. At one-year, the plaque volume in the biologic treated group decreased by 40 percent (p=0.002), a finding not observed in those without treatment (p=0.04). Trends in NCB and maximal stenosis were significant and consistent with PV in both groups. Furthermore, change in PV was also positively associated with a change in IL1B (β=0.56, p=0.03), even after adjustment for traditional cardiovascular risk factors and statin use.

“To see a reduction in coronary plaque after just one year of biologic therapy alone is incredible and very assuring. It’s the first time we’re seeing treatment of a skin disease with biologic therapy have an impact specifically on plaque in the coronary,” said Nehal N. Mehta, M.D., MSCE, FAHA, the principal investigator of the study from the National Heart, Lung, and Blood Institute. “Our study results further emphasize the importance of patients maintaining and treating psoriasis to decrease the risks of adverse cardiovascular events occurring. This also opens the door for us to look at other disease states and see how anti-inflammatory therapy options could impact coronary plaque over time.”

The authors of the study note that future, randomized studies are warranted to confirm these observational findings and to better understand how treatment with anti-inflammatory medications modulates coronary plaque volume over time.

Complete listing of SCAI 2018 late-breaking trials with links to articles.

References:

1. Amit Dey, Martin Playford, Aditya Joshi, et al. Improvement In Large Density HDL Particle Number by NMR is Associated with Improvement in Vascular Inflammation by 18-FDG PET/CT at One-Year in Psoriasis. Journal of the American College of Cardiology. Volume 71, Issue 11, Supplement, 10–12 March 2018, Page A1688

2. American Academy of Dermatology. Psoriasis: Who Gets and Causes. https://www.aad.org/public/diseases/scaly-skin/psoriasis#causes. Accessed April 201, 2018.

3. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006 Oct 11;296(14):1735-41.

4. Joseph B. Lerman, Aditya A. Joshi, Abhishek Chaturvedi, et al. Coronary Plaque Characterization in Psoriasis Reveals High Risk Features Which Improve Following Treatment in a Prospective Observational Study. 10.1161/CIRCULATIONAHA.116.026859

5. Paul M Ridker, Brendan M. Everett, Tom Thuren, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 2017; 377:1119-1131. DOI: 10.1056/NEJMoa1707914
 

Related Content

An example of a cardiac CT scan showing a 3-D reconstriction of the heart showing a stented vessel, and reformatted images showing the stented coronary artery with restenosis from different views. This was imaged using a Canon Aquilion Prime CT system.

An example of a cardiac CT scan showing a 3-D reconstriction of the heart showing a stented vessel, and reformatted images showing the stented coronary artery with restenosis from different views. This was imaged using a Canon Aquilion Prime CT system.

Feature | CT Angiography (CTA) | September 08, 2020
September 8, 2020 — The Journal of the Am
A calcium scoring CT scan showing a segment of heavily calcified coronary artery.

A calcium scoring CT scan showing a segment of heavily calcified coronary artery

News | CT Angiography (CTA) | August 20, 2020
August 20, 2020 – The amount of calcified plaque in the heart’s arteries on...
Sheer stresses on the walls of arteries are believed to cause the formation atherosclerotic plaques. This is an area of research that is expected to see increased use in the next few years. This study was presented at SCCT 2020 as an example of how sheer stresses can help evaluate and predict the patency of coronary artery bypass grafts (CABG). #SCCT2020 #yesCCT

Sheer stresses on the walls of arteries are believed to cause the formation atherosclerotic plaques. This is an area of research that is expected to see increased use in the next few years. This study was presented at SCCT 2020 as an example of how sheer stresses can help evaluate and predict the patency of coronary artery bypass grafts (CABG).

Feature | CT Angiography (CTA) | August 14, 2020 | Dave Fornell, Editor
The latest technical advances and trends in...
During the SCCT 2020 virtual meeting, SCCT President Ron Blackstein, M.D., Brigham and Women's, presents the SCCT Gold Award to John Lesser, M.D., MSCCT, director of advanced imaging and cardiac CT, Minneapolis Heart Institute, Abbott Northwestern Hospital. 

During the SCCT 2020 virtual meeting, SCCT President Ron Blankstein, M.D., Brigham and Women's, presented the SCCT Gold Award to John Lesser, M.D., MSCCT, director of advanced imaging and cardiac CT, Minneapolis Heart Institute, Abbott Northwestern Hospital. 

News | CT Angiography (CTA) | August 14, 2020 | Dave Fornell, Editor
An example of perivascular fat attenuation index (FAI) imaging inside the coronary vascular wall to show areas of inflammation. #SCCT2020

An example of perivascular fat attenuation index (FAI) imaging inside the coronary vascular wall to show areas of inflammation. The technology was created by Oxford University and several experts in cardiac CT imaging say this might be a game changer to improving risk assessments.

Feature | CT Angiography (CTA) | July 30, 2020 | Dave Fornell, Editor
There is a promising recent development in...
A cardiac CT of a patient with pacemaker leads, which can be challenging to get good images due to metal artifact. This image was rendered from using Canon's AiCE AI-assisted interactive reconstruction with Global Illumination 3-D rendering from a scan on an Aquilion One Genesis SP system.

A cardiac CT of a patient with pacemaker leads, which can be challenging to get good images due to metal artifact. This image was rendered from using Canon's AiCE AI-assisted interactive reconstruction with Global Illumination 3-D rendering from a scan on an Aquilion One Genesis SP system.

Feature | CT Angiography (CTA) | July 27, 2020 | Dave Fornell, Editor
There has been tremendous growth in the field of cardiovascular...
The new Aquilion One Genesis SP cardiac CT system uses artificial intelligence to help reconstruct low dose cardiac CT images. #SCCT2020

The new Aquilion One Genesis SP cardiac CT system uses artificial intelligence to help reconstruct low dose cardiac CT images.

News | CT Angiography (CTA) | July 20, 2020
July 20, 2020 – To meet the growing cardiovascular imaging needs of healthcare systems, Canon Medical Systems USA is